After filing for bankruptcy, rejected migraine drug developer Zosano’s value more than halved
The devastations of the public markets and the repeated rejections handed down by the FDA have added up to a dim future for Zosano Pharma as it appears the 16-year-old biotech’s journey is coming to an end.
The Fremont, CA biotech filed for bankruptcy on Wednesday and is currently operating as a “debtor-in-possession” and intends to rid itself of “substantially all of its assets” over the course of the Chapter 11 case, Zosano said Thursday morning.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.